Lazard Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Lazard Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,248	Closed	-$109K	–	2628
2022 Q3	$109K	Sell	7,248 -629	-8%	-$7.31K	﹤0.01%	1440
2022 Q2	$59K	Buy	+7,877	New	+$55.5K	﹤0.01%	1743
2022 Q1	–	Sell	-3,048	Closed	-$21K	–	2603
2021 Q4	$21K	Buy	+3,048	New	+$31.9K	﹤0.01%	2041
2021 Q2	–	Sell	-3,410	Closed	-$60K	–	2131
2021 Q1	$60K	Sell	3,410 -7,811	-70%	-$135K	﹤0.01%	1371
2020 Q4	$151K	Buy	+11,221	New	+$136K	﹤0.01%	1130

Lazard Asset Management's AERI Position: Q4 2022 in Review

Lazard Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 7,248 shares — an estimated $109K sold.

Lazard Asset Management first reported a position in AERI in Q4 2020 and held it in 5 quarters. The position peaked at $151K in Q4 2020. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Lazard Asset Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Lazard Asset Management sold 7,248 Aerie Pharmaceuticals shares in Q4 2022, an estimated $109K.
Lazard Asset Management first reported a position in Aerie Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Lazard Asset Management's Aerie Pharmaceuticals position peaked at $151K in Q4 2020.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Lazard Asset Management's 13F filing for Q4 2022, filed 15 Feb 2023.